Computational Commercial Validation of Relaxation Ingredient Systems Using CytoSolve® for British American Tobacco Innovation Programs

British American Tobacco (BAT) is a global consumer goods company investing in science-driven innovation across next-generation products and wellness-oriented formulations. BAT applies advanced research strategies to understand biological mechanisms underpinning consumer experiences such as relaxation and stress modulation.

Challenge

Relaxation and stress mitigation arise from highly interconnected biological systems involving neuroinflammation, neuroendocrine signaling, neurotransmission, and neuromodulatory pathways. While numerous bioactive ingredients have reported stress-relieving effects, their individual and combined mechanistic impacts across these systems were poorly understood. The lack of an integrated, quantitative framework limited rational ingredient selection, formulation optimization, and evidence-based commercialization of relaxation-oriented products.

How CytoSolve Helped

CytoSolve collaborated with British American Tobacco to conduct a comprehensive systems biology analysis of relaxation-related molecular pathways. CytoSolve:

  • Identified six major molecular pathway systems governing relaxation:
    • Gut microbiome–neuroinflammation signaling
    • Hypothalamic–pituitary–adrenal (HPA) axis signaling
    • Nerve growth factor signaling
    • Neurotransmitter signaling
    • Catecholamine signaling
    • Endocannabinoid signaling
  • Shortlisted six bioactive ingredients based on pathway efficacy: kaempferol, hypericin, withanone, ursolic acid, oleanic acid, and catechin.
  • Converted each relaxation-related pathway into validated mathematical models.
  • Integrated the plurality of models within the CytoSolve® platform to simulate ingredient-specific and system-wide effects in silico.
  • Quantified how individual and combined ingredients modulate stress-responsive biomarkers across molecular systems.

Key Benefits Realized

  • Systems-Level Relaxation Architecture
    Established the first integrated molecular map linking stress, neuroinflammation, neuroendocrine signaling, and neuromodulation.
  • Mechanistic Ingredient Differentiation
    Demonstrated how kaempferol, withanone, ursolic acid, oleanic acid, and catechin reduce stress-induced neuroinflammation via downregulation of IL-6 and IL-17 through the gut microbiome–brain axis.
  • Targeted Neuroendocrine Modulation
    Showed hypericin’s role in lowering cortisol via HPA axis modulation while upregulating GABA and BDNF signaling.
  • Balanced Neurotransmitter Regulation
    Identified ingredient-driven upregulation of serotonin and endocannabinoid signaling alongside downregulation of catecholamine and dopamine signaling.
  • Commercial Formulation Enablement
    Provided a quantitative framework to rationally design multi-ingredient relaxation products with synergistic biological effects.
  • Reduced Development Risk
    Enabled in silico testing of ingredient efficacy prior to experimental or market investment.

Outcome

Through its collaboration with CytoSolve®, British American Tobacco achieved a validated, systems-level mechanistic understanding of relaxation biology and ingredient-driven stress mitigation. The resulting computational architecture translated complex neurobiological interactions into actionable insights, enabling evidence-based ingredient selection and formulation strategies. This commercialization-ready platform demonstrates how CytoSolve® empowers consumer product innovators to de-risk development, substantiate functional claims, and transform molecular complexity into scalable, science-backed relaxation solutions.